返回 
加入收藏
乳腺癌伴慢性肾脏病患者的个体化治疗与药学监护
x
请在关注微信后，向客服人员索取文件
| 篇名： | 乳腺癌伴慢性肾脏病患者的个体化治疗与药学监护 |
| TITLE： | Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease |
| 摘要： | 目的 为乳腺癌伴慢性肾脏病（CKD）患者的个体化治疗和临床药学实践提供参考。方法临床药师参与1例乳腺癌伴CKD患者的抗肿瘤治疗过程并提供药学监护。临床药师查阅指南与文献，协助医生制定术前初始新辅助化疗方案（多西他赛+曲妥珠单抗+帕妥珠单抗），并就方案所含药物可能引发的呕吐、骨髓抑制、肾功能损害、心脏毒性等不良反应提出监护建议；针对患者治疗后出现的急性肾损伤，临床药师通过关联性评价协助医生分析不良反应产生原因，并结合患者意愿，将多西他赛替换为紫杉醇（无需根据肾功能调整剂量）；临床药师协助医生确定术后靶向治疗方案（曲妥珠单抗+帕妥珠单抗），考虑到患者为雌激素受体阳性，建议其在放疗结束后规律服用阿那曲唑并定期检测骨密度。结果医生接受临床药师建议。患者顺利完成术前新辅助化疗和术后靶向治疗，带药（阿那曲唑）出院；治疗期间，未出现骨髓抑制、心脏毒性等不良反应，后续也未发生骨质疏松。结论临床药师根据患者肾功能分析调整术前/术后抗肿瘤治疗方案，及时评估抗肿瘤药物与急性肾损伤的关联性，积极开展全流程药学监护，保障了乳腺癌伴CKD患者的用药安全。 |
| ABSTRACT： | OBJECTIVE To provide a reference for individualized treatment and pharmaceutical care for patients with breast cancer complicated with chronic kidney disease （CKD）. METHODS Clinical pharmacists participated in the anti-tumor treatment and pharmaceutical care for a breast cancer patient with CKD. Clinical pharmacists reviewed guidelines and literature to assist the clinical physician in formulating the initial neoadjuvant treatment plan （docetaxel+trastuzumab+paltuzumab） and provided monitoring recommendations for potential adverse drug reactions， such as vomiting， myelosuppression， renal impairment， cardiotoxicity. In response to the patient’s acute kidney injury after treatment， clinical pharmacists assisted the physician in analyzing the cause of the adverse reaction through causality assessment. Taking into account the patient’s preferences， docetaxel was substituted with paclitaxel （which did not require dose adjustment based on renal function）. The clinical pharmacists collaborated with the physician to establish a postoperative targeted therapy regimen （trastuzumab+pertuzumab）. Taking into account the patient’s positive estrogen receptor status， the clinical pharmacists recommended to initiate regular anastrozole administration after the completion of radiotherapy and undergo periodic bone density assessments. RESULTS The clinical physician accepted the suggestions from the clinical pharmacists. The patient successfully completed preoperative neoadjuvant chemotherapy and postoperative targeted therapy， and was discharged with medication （anastrozole）. During the treatment process， the patient did not experience adverse reactions such as myelosuppression， cardiotoxicity， or the occurrence of osteoporosis. CONCLUSIONS Clinical pharmacists analyzed and adjusted the preoperative and postoperative antitumor treatment plans based on the patient’s renal function. They promptly assessed the correlation between antitumor drugs and acute kidney injury， and actively implemented comprehensive pharmaceutical care to ensure medication safety for breast cancer patients with CKD. |
| 期刊： | 2025年第36卷第07期 |
| 作者： | 俞璐；吴旭栋；张明 |
| AUTHORS： | YU Lu，WU Xudong，ZHANG Ming |
| 关键字： | 乳腺癌；慢性肾脏病；术前新辅助化疗；术后靶向治疗；临床药师；药学监护 |
| KEYWORDS： | breast cancer； chronic kidney disease； preoperative neoadjuvant treatment； postoperative targeted therapy； clinical |
| 阅读数： | 7 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
